Paperpal Prime Logo

Dose-Response : Impact Factor & More

eISSN: 1559-3258pISSN: 1559-3258
JournalOpen Access

Key Metrics

CiteScore
3.5
Impact Factor
< 5
SJR
Q3Toxicology
SNIP
0.74
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Dose-Response

Dose-Response Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SAGE PUBLICATIONS INC
Language English
Frequency Quarterly
Article Processing ChargesUSD 2000
Publication Time15
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2006
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 15
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Dose-Response ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Dose-Response

Association of Type 2 Diabetes Mellitus and Risk of Colorectal Cancers in Pyogenic Liver Abscess
  • 3 Aug 2026
  • Dose-Response
Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma
  • 25 Jul 2026
  • Dose-Response
Cnicin Attenuates Aluminium Chloride\u2013Induced Neurodegeneration Through Antioxidant and Anti-Inflammatory Mechanisms
  • 24 Jul 2026
  • Dose-Response
Mechanistic Insights Into Dose-Dependent Alleviation of Colorectal Cancer Through Artemisinin-Loaded Mesoporous Silica Nanoparticles in 1,2-Dimethylhydrazine-Induced Albino Wistar Rats
  • 23 Jul 2026
  • Dose-Response
Integrating Network Pharmacology and Experimental Validation Reveals EGFR/PI3K/Akt Axis Mediates Ibrutinib-Induced Cardiotoxicity
  • 23 Jul 2026
  • Dose-Response
Dose Reconstruction After a WD\u2012XRF Spectrometer Accident Using Minute-Rate TLD Measurements
  • 23 Jul 2026
  • Dose-Response
Association of Type 2 Diabetes Mellitus and Risk of Colorectal Cancers in Pyogenic Liver Abscess
  • 3 Aug 2026
  • Dose-Response
Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma
  • 25 Jul 2026
  • Dose-Response
Cnicin Attenuates Aluminium Chloride\u2013Induced Neurodegeneration Through Antioxidant and Anti-Inflammatory Mechanisms
  • 24 Jul 2026
  • Dose-Response
Mechanistic Insights Into Dose-Dependent Alleviation of Colorectal Cancer Through Artemisinin-Loaded Mesoporous Silica Nanoparticles in 1,2-Dimethylhydrazine-Induced Albino Wistar Rats
  • 23 Jul 2026
  • Dose-Response
Integrating Network Pharmacology and Experimental Validation Reveals EGFR/PI3K/Akt Axis Mediates Ibrutinib-Induced Cardiotoxicity
  • 23 Jul 2026
  • Dose-Response
Dose Reconstruction After a WD\u2012XRF Spectrometer Accident Using Minute-Rate TLD Measurements
  • 23 Jul 2026
  • Dose-Response

FAQs on Dose-Response